The recent conditional US Food and Drug Administration (FDA) approval of two therapies, resmetirom (Rezdiffra) and semaglutide (Wegovy), marks the first time clinicians have pharmacological therapy for metabolic dysfunction-associated steatohepatitis (MASH) with significant fibrosis (F2-F3) without cirrhosis, a disease...
Maria Mironova, Vlad Ratziu, M. Rinella et al.· Gut· 0 citations
BACKGROUND
Thyroid hormone receptor β (THR-β) agonists reduce atherogenic lipids, hepatic fat, and improve histology in metabolic dysfunction-associated steatohepatitis (MASH). The phase 2a HERALD study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of the selective and potent THR-β agonist ALG-...
R. Loomba, Stanley Wang, Dimple Desai et al.· The Lancet Gastroenterology...· 0 citations
BACKGROUND & AIMS
Cirrhosis from metabolic dysfunction-associated steatotic liver disease (MASLD) usually develops with advancing age, yet a subset of patients presents at younger ages. We examined genetic and metabolic factors associated with younger-onset MASLD cirrhosis.
APPROACH AND RESULTS
Adults with biopsy-pro...
Veeral H. Ajmera, Linus Schwantes-An, Luis Antonio Díaz et al.· Clinical Gastroenterology an...· 0 citations
BACKGROUND AND AIMS
The American Association for the Study of Liver Diseases (AASLD) recommends that a decline in liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) can be used as a non-invasive endpoint for treatment response in metabolic dysfunction-associated steatohepatitis (MAS...
R. Loomba, Rui-Qiu Chen, You-Xin Wang et al.· Hepatology· 0 citations
ABSTRACT Detecting metabolic dysfunction-associated steatohepatitis (MASH) before fibrosis develops remains a major challenge. We used a longitudinal streptozotocin/high-fat diet (STAM/HFD) mouse model to identify microbial and metabolic features that emerge before histological MASH onset. Integrative 16S rRNA and unta...
Stephany Flores Ramos, Kelly A. Fogelson, V. Muti et al.· mSystems· 0 citations
Key research priorities include refining epidemiological estimates, standardizing biomarker cut-offs, elucidating dynamic interactions between alcohol and CMRFs, validating non-invasive prognostic tools, and evaluating therapies that target both metabolic and alcohol-related injury.
L. Díaz, E. Pose, Mads Israelsen et al.· Nature reviews: Gastroentero...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.